Vancomycin and piperacillin-tazobactam against methicillin-resistant staphylococcus aureus and vancomycin-intermediate staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model

Clinical Therapeutics

Volumn 36, Issue 10, 2014, Pages 1334-1344

  Dilworth, Thomas J ^a,b   Leonard, Steve N ^c   Vilay, A Mary ^a   Mercier, Renée Claude ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b Wheaton Franciscan Healthcare St Francis   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

combination therapy; methicillin resistant Staphylococcus aureus; piperacillin tazobactam; vancomycin; vancomycin intermediate Staphylococcus aureus

Indexed keywords

OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG HALF LIFE; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NONHUMAN; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; DRUG EFFECTS; DRUG POTENTIATION; MICROBIAL SENSITIVITY TEST; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DRUG SYNERGISM; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PENICILLANIC ACID; PIPERACILLIN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84908272821     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.06.027     Document Type: Article

References (40)

1. C.J. Walraven, M.S. North, L. Marr-Lyon, P. Deming, G. Sakoulas, and R.C. Mercier Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia J Antimicrob Chemother 66 2011 2386 2392
2. B.P. Howden, P.B. Ward, and P.G. Charles Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility Clin Infect Dis 38 2004 521 528
3. V.H. Chu, D.R. Crosslin, and J.Y. Friedman Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes Am J Med 118 2005 1416
4. E. Cosgrove, G. Sakoulas, E.N. Perencevich, M.J. Schwaber, A.W. Karchmer, and Y. Carmeli Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis Clin Infect Dis 36 2003 53 59
5. P.G. Charles, P.B. Ward, P.D. Johnson, B.P. Howden, and M.L. Grayson Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus Clin Infect Dis 38 2004 448 451
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 13, 2014.
7. H.M. Blumberg, M.K. Leonard Jr, and R.M. Jasmer Update on the treatment of tuberculosis and latent tuberculosis infection JAMA 293 2005 2776 2784
8. M. Niederman, D. Craven, and M. Bonten Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
9. T.J. Dilworth, J. Sliwinski-Heath, K. Ryan, M. Dodd, and R.C. Mercier Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate S. aureus isolates in vitro Antimicrob Agent Chemother 58 2014 1028 1033
10. S.M. Palmer, and M.J. Rybak An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots J Antimicrob Chemother 39 1997 515 518
11. B.J. Werth, C. Vidaillac, K.P. Murray, K.L. Newton, G. Sakoulas, P. Nonejuie, J. Pogliano, and M.J. Rybak Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA) Antimicrob Agents Chemother 57 2013 2376 2379
12. S.N. Leonard Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model PloS One 7 2012 e42103
13. M. Hagihara, D.E. Wiskirchen, J.L. Kuti, and D.P. Nicolau In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 56 2012 202 207
14. T.J. Dilworth, O. Ibrahim, P. Hall, J. Sliwinski, C. Walraven, and R.C. Mercier β-Lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone Antimicrob Agents Chemother 58 2014 102 109
15. S. Rochon-Edouard, M. Pestel-Caron, J.F. Lemeland, and F. Caron In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains Antimicrob Agents Chemother 44 2000 3055 3060
16. L. Drago, E. De Vecchi, L. Nicola, and M.R. Gismondo In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections BMC Infect Dis 7 2007 111
17. G.P. Allen, R. Cha, and M.J. Rybak In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model Antimicrob Agents Chemother 46 2002 2606 2612
18. H. Hanaki, Y. Yamaguchi, and S. Nomura Method of detecting β-lactam antibiotic induced vancomycin resistant MRSA (BIVR) Int J Antimicrob Agents 23 2004 1 5
19. Yamaguchi Y Hanaki, and K. Barata Improved method of detection of β-lactam antibiotic-induced VCM-resistant MRSA (BIVR) Int J Antimicrob Agents 23 2004 311 313
20. R.P. Dellinger, M.M. Levy, and A. Rhodes Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 Intensive Care Med 39 2013 165 228
21. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. 2011. Clinical and Laboratory Standards Institute, Wayne, PA
22. Etest for MIC determination [package insert]. Solna, Sweden: BioMerieux Inc., 2009.
23. M.J. Rybak, B.M. Lomaestro, and J.C. Rotschafer Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists Clin Infect Dis 49 2009 325 327
24. S. Keil, and B. Wiedemann Mathematical corrections for bacteria loss in pharmacodynamic in vitro dilution models Antimicrob Agents Chemother 39 1995 1054 1058
25. C. Li, J.L. Kuti, C.H. Nightingale, D.L. Mansfield, A. Dana, and D.P. Nicolau Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection J Antimicrob Chemother 56 2005 388 395
26. S.C. Marselos, and H.A. Archontaki Development and optimization of a reversed-phase high-performance liquid chromatographic method for the determination of piperacillin and tazobactam in tazocin injectable powder J Pharm Biomed Anal 29 2001 787 793
27. M. Wootton, R.A. Howe, R. Hillman, T.R. Walsh, P.M. Bennett, and A.P. MacGowan A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital J Antimicrob Chemother 47 2001 399 403
28. W.E. Rose, S.N. Leonard, K.L. Rossi, G.W. Kaatz, and M.J. Rybak Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model Antimicrob Agents Chemother 53 2009 805 807
29. K.L. LaPlante, and M.J. Rybak Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model Antimicrob Agents Chemother 48 2004 4665 4672
30. T. Takata, M. Miyazaki, and M. Futo Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection Scand J Infect Dis 45 2013 203 212
31. J.A. Roberts, S.K. Paul, and M. Akova DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 2014 1072 1083
32. Burgess LD, Drew RH. Comparison of the Incidence of Vancomycin-Induced Nephrotoxicity in Hospitalized Patients with and without Concomitant Piperacillin-Tazobactam. Pharmacotherapy. 2014 May 22. [Epub ahead of print].
33. Gomes DM, Smotherman C, Birch A, et al. Comparison of Acute Kidney Injury During Treatment with Vancomycin in Combination with Piperacillin-Tazobactam or Cefepime. Pharmacotherapy. 2014 Apr 18. [Epub ahead of print].
34. A.D. Berti, G. Sakoulas, V. Nizet, R. Tewhey, and W.E. Rose β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 57 2013 5005 5012
35. rd Annual Interscience Conference for Antimicrobial Agents and Chemotherapy. September 2013. Denver, CO. Abstract A-021.
36. A. Dhand, A.S. Bayer, and J. Pogliano Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding Clin Infect Dis 53 2011 158 163
37. B.J. Werth, G. Sakoulas, W.E. Rose, J. Pogliano, R. Tewhey, and M.J. Rybak Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model Antimicrob Agents Chemother 57 2013 66 73 10.1128/AAC.01586-12
38. K. Sieradzki, and A. Tomasz Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics J Antimicrob Chemother 39 Suppl A 1997 47 51
39. S.J. Yang, Y.Q. Xiong, S. Boyle-Vavra, R. Daum, T. Jones, and A.S. Bayer Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect") Antimicrob Agents Chemother 54 2010 3161 3169
40. J.K. Ortwine, B.J. Werth, G. Sakoulas, and M.J. Rybak Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the "seesaw effect": taking advantage of the back door left open? Drug Resist Updat 16 2013 73 79